Skip to content
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Newsroom Recursion announced that CEO and President Najat Khan will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and that management will also participate in the 28th Annual Needham Growth Conference on January 16, 2026. The appearances provide investors with continued access to

DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

DemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)

✨ Onyx Summary DemeRx, Inc. reported positive Phase 1 multiple ascending dose results for DMX-1001, showing the oral noribogaine candidate was safe, well-tolerated, and exhibited pharmacokinetics that support advancement into Phase 2 trials for alcohol use disorder. The data position DemeRx, Inc. to progress a differentiated neurorestorative approach in a treatment

3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors

3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors

✨ Onyx Summary 3T Biosciences appointed Behzad Kharabi, M.D., as chief medical officer and Parker Institute for Cancer Immunotherapy CEO Karen E. Knudsen, Ph.D., MBA, to its board of directors as it advances its bispecific T-cell engager pipeline for solid tumors. The additions strengthen the company’s clinical development

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the J.P. Morgan Healthcare Conference on January 14, 2026, highlighting the company’s autoimmune-focused cell therapy strategy to the investment community. The presentation signals Kyverna’s continued engagement with global healthcare investors as it advances its clinical

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of the “100 Most Influential People in Oncology in 2025”

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of the “100 Most Influential People in Oncology in 2025”

✨ Onyx Summary ImmunityBio announced that OncoDaily has named its founder and executive chairman, Patrick Soon-Shiong, to The 100 Most Influential People in Oncology in 2025. The recognition underscores Soon-Shiong’s long-standing impact on oncology research and leadership, reinforcing ImmunityBio’s scientific credibility and visibility within the global cancer research and

enGene Reports Full Year 2025 Financial Results and Provides Business Update

enGene Reports Full Year 2025 Financial Results and Provides Business Update

✨ Onyx Summary enGene Holdings Inc. reported full-year 2025 financial results and a business update, highlighting completion of enrollment in the pivotal LEGEND cohort for detalimogene in BCG-unresponsive NMIBC and a cash position of $342.4 million, extending operating runway into the second half of 2028. The company outlined plans to

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy

✨ Onyx Summary Sinaptica Therapeutics announced the completion of its Scientific Advisory Board, assembling experts across neuroscience, clinical development, neuromodulation, patient advocacy, and commercialization to guide the company through its upcoming pivotal Alzheimer’s disease trial. The expanded board strengthens Sinaptica’s strategic positioning at a key inflection point, supporting clinical

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Geron Corporation granted stock options covering 320,000 shares to a newly hired employee as an inducement award, with options priced at the December 17, 2025 closing share price and vesting over four years in accordance with Nasdaq rules and the company’s inducement equity plan. FOSTER CITY,

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Perspective Therapeutics announced that Chief Executive Officer Thijs Spoor will present at the J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. SEATTLE, Dec. 18, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Legend Biotech Corporation announced that CEO Ying Huang will present a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a live webcast and replay available via the company’s investor relations website. SOMERSET, N.J.,Dec. 17, 2025 – Legend Biotech

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

✨ Onyx Summary ImmunityBio reported long-term Phase 2/3 QUILT-3.032 data showing that ANKTIVA plus BCG delivered durable disease-free, progression-free, and disease-specific survival, with high cystectomy avoidance through 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer. Published in The Journal of Urology, the findings extend evidence

nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B

nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B

✨ Onyx Summary nChroma Bio said it has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of CRMA-1001 for the treatment of chronic hepatitis B. The approval advances a novel epigenetic silencing approach into the clinic, positioning the company to address a large unmet global